<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759250</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-110-1401</org_study_id>
    <nct_id>NCT02759250</nct_id>
  </id_info>
  <brief_title>A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)</brief_title>
  <official_title>A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>arGEN-X BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>arGEN-X BVBA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the safety profile of ARGX-110 administered as mono- or combination therapy
      to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">April 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and grading of AEs</measure>
    <time_frame>measured at screening, Day 1, Day 8, Day 15, Day 42, thereafter every 42 days until Day 378</time_frame>
    <description>Change from baseline in incidence and grading of AEs according to the Common Terminology Criteria for Adverse Event (NCI-CTCAE) Version 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of ARGX110 by Cmax</measure>
    <time_frame>measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378</time_frame>
    <description>Change from baseline in Measurement of drug concentration in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of ARGX110 by AUC</measure>
    <time_frame>measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378</time_frame>
    <description>Change in Measurement of drug concentration in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers CD70 immunohistochemistry (IHC)</measure>
    <time_frame>measured at Screening, Day 42, and thereafter every 42 days until day Day 378</time_frame>
    <description>Change in Measurement of concentration in tumor tissue</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>adjuvant monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-110 5mg/kg once every three weeks for a maximum of 18 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metastatic/recurrent monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-110 5mg/kg once every three weeks until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metastatic/recurrent combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-110 5mg/kg once every three weeks plus chemotherapy until disease progression. The choice of the chemotherapy agents is limited to: cisplatin, carboplatin, 5-fluorouracil, gemcitabine and paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARGX-110</intervention_name>
    <arm_group_label>adjuvant monotherapy</arm_group_label>
    <arm_group_label>metastatic/recurrent monotherapy</arm_group_label>
    <arm_group_label>metastatic/recurrent combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥18 years.

          -  Written informed consent prior to any study-related procedure

          -  Willing and able to comply with protocol-specified procedures and scheduled
             evaluations

          -  Pathological diagnosis of nasopharyngeal carcinoma (NPC)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1or 2

          -  Absolute neutrophil count (ANC) &gt; 0.5 x 109/L

          -  Haemoglobin &gt; 80 g/L

          -  Platelet count ≥ 50 x 109/L

          -  Total bilirubin ≤ 2 x the upper limit of normal (ULN)

          -  Alanine transaminase (ALT) ≤ 5 x ULN

          -  Serum creatinine ≤ 2 x ULN

        Exclusion criteria:

          -  History or clinical evidence of neoplastic central nervous system (CNS) involvement.
             Note: Irradiated brain metastases that have been stable for &gt; 1 month and do not
             require systemic glucocorticoid administration are allowed

          -  Major surgery within 4 weeks of ARGX-110 first dose administration

          -  Unresolved grade 3 or 4 toxicity from prior therapy (except mucositis from local
             radiation therapy).

          -  Active, untreated viral, bacterial, or systemic fungal infection

          -  Childbearing potential unless using an adequate measure of contraception

          -  Pregnancy or lactation. History of hypersensitivity to recombinant proteins

          -  Any clinical finding, including psychiatric and behavioural problems, which, in the
             opinion of the Investigator, precludes the patient from safely participating in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Rottey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZG - Universitair Ziekenhuis Gent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZG - Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

